A5009577647- Psoriasis: Treatment and Pathogenesis
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Spondyloarthritis Studies and Treatments
- Oral microbiology and periodontitis research
- Autoimmune and Inflammatory Disorders Research
- Autoimmune Bullous Skin Diseases
- IL-33, ST2, and ILC Pathways
- Rheumatoid Arthritis Research and Therapies
UCB Pharma (United Kingdom)
2023-2024
Centre for Inflammation Research
2018-2019
King's College London
2016-2019
The Th17/IL-17 pathway is implicated in the pathogenesis of periodontitis (PD), however mechanisms are not fully understood. We investigated mechanism by which periodontal pathogens Porphyromonas gingivalis (Pg) and Aggregatibacter actinomycetemcomitans (Aa) promote a response vitro, studied IL-17(+) CD4(+) T-cell frequencies gingival tissue peripheral blood from patients with PD versus periodontally healthy controls. Addition Pg or Aa to monocyte/CD4(+) co-cultures promoted vitro dose-...
Abstract The pro‐inflammatory cytokine IL‐17A has been implicated in the immunopathology of inflammatory arthritis. IL‐17F bears 50% homology to and recently suggested play a role inflammation. We investigated induction profile + CD4 T cells, how may contribute Upon culture healthy donor cells with IL‐1β, IL‐23, anti‐CD3, anti‐CD28 mAb, both IL‐17F‐expressing were detected. In comparison − contained lower proportions IL‐10‐expressing GM‐CSF‐expressing higher IFN‐γ‐expressing cells. Titration...
Abstract Background/Aims Certolizumab pegol (CZP), a PEGylated TNFi without an Fc region, has previously shown efficacy and safety in patients with axial spondyloarthritis (axSpA). EULAR guidelines recommend that tapering of biologic can be considered for sustained remission. The C-OPTIMISE trial (NCT02505542) identified early (<5 years) axSpA remission who may benefit from dose or stopping treatment. Here we report whether reduced CZP maintenance is associated improvements patient...